China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

One of the most promising avenues in treating cancer is to restore our immune system’s ability to recognize and attack cancerous cells.

AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO).

Moderna and Thermo Fisher Scientific Inc.announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.

Belgian diagnostics firm MDxHealth on Wednesday reported a 20 percent year-over-year increase in revenues for 2021 on higher demand for its ConfirmMDx prostate cancer test.

Lucid Diagnostics on Thursday announced that its LucidDx Labs subsidiary has acquired certain licenses and other related assets from ResearchDx enabling it to operate a new CLIA-certified, CAP-accredited clinical laboratory in Lake Forest, California.

Today, Beckman Coulter announced that Dr. Tiffany Jiang, Senior Vice President & General Manager, retired early effective February 28.

New research led by Queen Mary University of London and Barts Health NHS Trust suggests that biochemical analysis of brain tissue could be used for diagnosis and prognosis of severe traumatic brain injury (TBI) to improve patient outcomes and save billions in future clinical trials.

On March 2，BioMérieux reported that its fourth quarter revenues rose 8 percent year over year.

Veracyte reported after the close of the market on Monday that its fourth quarter revenues nearly doubled year over year.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Julie L. Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from Merck in May 2022.